BACKGROUND: To determine the impact of race and other factors on the management and outcomes of women treated for cervical cancer in a rural state. METHODS: Following IRB approval, a retrospective review identified 434 eligible women treated for cervical cancer from 1994 to 2000. Collected data included: demographics, clinicopathologic data, primary and adjuvant therapy, recurrence, and survival. Statistical analyses were performed with the Chi-square test, Kaplan-Meier method, and Cox regression. RESULTS: 304 (70%) of the women were white and 130 (30%) were non-white. Non-whites were more likely to present with advanced stage disease [Stage IIB-IVB] (25% vs. 13%; P < 0.01). Whites were more likely to smoke, be married, be employed, and have private insurance. Non-whites were more likely to have medical co-morbidities such as diabetes and hypertension. Although whites with early stage disease were more likely to undergo surgery as their primary therapy than non-whites (93% vs. 84%; P < 0.01), survival was similar. Survival outcomes for advanced stage disease were similar between groups. CONCLUSIONS: Non-whites diagnosed with cervical cancer are more likely to present with advanced stage disease than whites; however, overall survival was similar between groups. Non-whites with early stage disease were more likely to receive primary radiation therapy than whites. The decision to use radiation therapy vs. surgery does not appear to have a detrimental effect on overall survival, but may impact quality of life.
BACKGROUND: To determine the impact of race and other factors on the management and outcomes of women treated for cervical cancer in a rural state. METHODS: Following IRB approval, a retrospective review identified 434 eligible women treated for cervical cancer from 1994 to 2000. Collected data included: demographics, clinicopathologic data, primary and adjuvant therapy, recurrence, and survival. Statistical analyses were performed with the Chi-square test, Kaplan-Meier method, and Cox regression. RESULTS: 304 (70%) of the women were white and 130 (30%) were non-white. Non-whites were more likely to present with advanced stage disease [Stage IIB-IVB] (25% vs. 13%; P < 0.01). Whites were more likely to smoke, be married, be employed, and have private insurance. Non-whites were more likely to have medical co-morbidities such as diabetes and hypertension. Although whites with early stage disease were more likely to undergo surgery as their primary therapy than non-whites (93% vs. 84%; P < 0.01), survival was similar. Survival outcomes for advanced stage disease were similar between groups. CONCLUSIONS: Non-whites diagnosed with cervical cancer are more likely to present with advanced stage disease than whites; however, overall survival was similar between groups. Non-whites with early stage disease were more likely to receive primary radiation therapy than whites. The decision to use radiation therapy vs. surgery does not appear to have a detrimental effect on overall survival, but may impact quality of life.
Authors: Anne Marie McCarthy; Tamara Dumanovsky; Kala Visvanathan; Amy R Kahn; Maria J Schymura Journal: Cancer Causes Control Date: 2010-06-03 Impact factor: 2.506
Authors: T Clark Powell; Sarah E Dilley; Sejong Bae; J Michael Straughn; Kenneth H Kim; Charles A Leath Journal: J Low Genit Tract Dis Date: 2018-10 Impact factor: 1.925
Authors: David A Barrington; Sarah E Dilley; Emily E Landers; Eric D Thomas; Jonathon D Boone; J Michael Straughn; Gerald McGwin; Charles A Leath Journal: Gynecol Oncol Date: 2016-10-06 Impact factor: 5.482
Authors: Krista S Pfaendler; Jenny Chang; Argyrios Ziogas; Robert E Bristow; Kristine R Penner Journal: Obstet Gynecol Date: 2018-05 Impact factor: 7.661
Authors: Sujana Movva; Anne-Michelle Noone; Mousumi Banerjee; Divya A Patel; Kendra Schwartz; Cecilia L Yee; Michael S Simon Journal: Cancer Date: 2008-03-15 Impact factor: 6.860
Authors: Naomi Brewer; Barry Borman; Diana Sarfati; Mona Jeffreys; Steven T Fleming; Soo Cheng; Neil Pearce Journal: BMC Cancer Date: 2011-04-12 Impact factor: 4.430
Authors: Janaka Weragoda; Andres Azuero; Suguna Badiga; Walter C Bell; Roland Matthews; Chandrika Piyathilake Journal: Cancer Med Date: 2016-05-17 Impact factor: 4.452